Page 103 - NobleCon21

Intelligent Bio Solutions Inc.

SELECTED FINANCIAL ITEMS INBS
(in millions of USD)
CQ4 '24 CQ1 '25 CQ2 '25 CQ3 '25 LTM
Income Statement Key Items
Total Revenue 0.61 0.73 0.84 1.11 3.29
Gross Profit 0.22 0.34 0.34 0.52 1.42
Gross Margin 37% 47% 40% 47% 43%
EBIT (2.26) (2.55) (2.88) (2.74) (10.44)
EBIT Margin -373% -350% -341% -246% -317%
Net Income to Common Shareholders (2.26) (2.55) (3.10) (2.99) (10.91)
Net Margin -371% -350% -368% -269% -331%

Balance Sheet Key Items
Total Assets 8.68 9.58 8.25 10.04 10.04
Cash & Short Term Investments 2.24 2.81 1.02 1.66 1.66
% of Assets 26% 29% 12% 17% 17%
Current Assets -Total 4.06 5.11 4.14 4.48 4.48
% of Assets 47% 53% 50% 45% 45%
Total Liabilities 4.48 4.64 5.44 6.61 6.61
% of Assets 52% 48% 66% 66% 66%
Current Liabilities - Total 4.40 4.56 5.35 5.06 5.06
% of Assets 51% 48% 65% 50% 50%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 4.20 4.94 2.81 3.43 3.43
% of Assets 48% 52% 34% 34% 34%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (2.32) (2.76) (2.21) (2.85) (10.14)
Net Cash Flow - Investing (0.01) (0.01) (0.21) (0.07) (0.30)
Net Cash Flow - Financing 0.63 3.32 0.60 3.56 8.11

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference